FLT3 and acute myeloid leukemia: Thus, we identified the combination of ABT-737, a B-cell lymphoma (BCL)-family inhibitor, and Purvalanol A, a cyclin dependent kinase (CDK)-inhibitor, as a potential targeted therapy for AML patients carrying a mixed lineage leukaemia (MLL) rearrangement and internal tandem duplications of the fms-related tyrosine kinase 3 gene (FLT3-ITD).